Molecular alterations compromising key metabolic pathways are poorly understood in sporadic frontotemporal lobar degeneration with TDP-43 pathology (sFTLD-TDP). Whole-transcriptome array, RT-qPCR validation, gel electrophoresis, and Western blotting, and mitochondrial electron transport chain (ETC) activity were comparatively examined in frontal cortex (area 8) of 16 sFTLD-TDP cases and 14 controls. Assessment of 111 genes by RT-qPCR showed deregulation of 81 genes linked to neurotransmission and synapses, neuronal architecture, cytoskeleton of axons and dendrites, vesicle trafficking, purines, mitochondria, and energy metabolism in sFTLD-TDP. Western blotting studies disclosed downregulation of several mitochondrial subunits encoded by genomic DNA and MT-CO1 encoded by the mitochondrial DNA. Mitochondrial ETC activity of complexes I, IV, and V was decreased in sFTLD-TDP. These findings provide robust information about downregulation of genes involved in vital biochemical pathways and in synaptic neurotransmission which may help to increase understanding about the biochemical substrates of clinical manifestations in sFTLD-TDP.
INTRODUCTION
Frontotemporal dementia is a progressive neurological disorder characterized by deterioration of personality, behavior, language, and cognition, with marked individual variations, and in the majority of patients is due to frontotemporal lobar degeneration (FTLD). This term stresses the progressive loss of neurons in the frontal and temporal lobes as the cause of the principal neurological symptoms. FTLD is not a unique disease but covers several unrelated conditions: 1) FTLD-tau is identified by the abnormal tau deposition in neurons and glial cells, which in turn encompasses sporadic and genetic forms associated with mutations in MAPT, the gene coding for protein tau; and 2) FTLD-U, which is characterized by the presence of intraneuronal ubiquitin-immunoreactive inclusions. Subsequent studies have demonstrated the heterogeneity of FTLD-U, including FTLD-TDP-43 proteinopathy, FTLD-FUS proteinopathy, and FTLD-UPS, lacking TDP-43 and FUS inclusions (1) (2) (3) .
FTLD-TDP-43 proteinopathy (FTLD-TDP) is clinically manifested by behavioral-dysexecutive disorder, primary progressive aphasia and/or motor disorders including motor neuron disease; macroscopically, by frontal and temporal atrophy, commonly symmetrical, variable involvement of the basal ganglia and substantia nigra; and microscopically, by neuron loss in the cerebral cortex, microvacuolation in the upper cortical layers, astrogliosis, and TDP-43-immunoreactive inclusions in the nucleus and/or cytoplasm of neurons and oligodendocytes, and in neuropil threads (1) (2) (3) . Some cases are sporadic (sFTLD-TDP) whereas other are genetic, often familial (fFTLD-TDP) and linked to mutations in different genes including GRN (progranulin), C9ORF72 (chromosome 9 open reading frame 72), TARDP (TAR DNA-binding protein), VCP (valosin-containing protein), CHMBP2 (charged multivesicular body protein 2), and UBQLN (ubiquilin 2), among others (4) (5) (6) . Excepting progranulin, mutations of any of the other genes may also be causative of amyotrophic lateral sclerosis (ALS), thus suggesting ALS/FTLD-TDP within the same 8082ifa@gmail.com This study was supported by grants from CIBERNED and PI17/00809 Institute of Health Carlos III, and cofunded by FEDER funds/European Regional Development Fund (ERDF)-a way to build Europe; ALS intra-CIBERNED project to IF; and IFI15/00035 fellowship to PA-B; grant "Retos todos unidos contra la ELA" to MP; and grant from the "Fundaci on Tatiana P erez de Guzm an el Bueno, convocatoria Neurociencias 2014" to EG. The authors have no competing interests to declare. disease spectrum (7) (8) (9) . The presence of TDP-43 inclusions in ALS together with the characteristics of TDP-43, which is phosphorylated, ubiquitinated, and truncated at the C-terminal in both conditions (10) , argues in favor of these bounds.
FTLD-TDP has been subclassified into 4 different neuropathologic subgroups that roughly correlate with certain clinical symptoms and genetic substrates although with low predictive value (11, 12) . Type A is characterized by numerous neuronal cytoplasmic inclusions (NCIs) and dystrophic neurites (DNs), and variable number of neuronal nuclear inclusions (NIIs) predominating in the upper cortical layers. Type B is delineated by numerous NCIs in the upper and inner cortical layers, and low numbers of DNs and NIIs. Type C is defined by predominant DNs in the upper cortical layers and rare NCIs and NIIs. Type D is characterized by predominance of NIIs, and rare NCIs and DNs (1, 11, 12) .
The study of human brain tissue has been useful to unveil additional molecular alterations in FTLD-TDP (13) . Complementary information has been obtained using proteomics and transcriptomics in a limited number of FTLD-TDP subtypes including those linked with GRN and C9Orf72 mutations, and atypical FTLD-TDP cases (14) (15) (16) (17) . Gene expression profile has also been recently described in the frontal cortex area 8 in ALS (18) and in different brain regions in sporadic ALS and ALS linked to C9Orf72 mutations (19) . However, the molecular pathology of metabolic pathways, mitochondria and energy metabolism, synapses, and neurotransmission has not been studied in sFTLD-TDP. The present study was aimed at analyzing gene expression in frontal cortex area 8 in a series of sFTLD-TDP in parallel with controls in order to gain understanding about vulnerable pathways which can explain pathogenic aspects of the disease.
MATERIALS AND METHODS

Human Cases
Brain samples were obtained from the Brain Banks of the Institute of Neuropathology HUB-ICO-IDIBELL Biobank and the Hospital Clinic-IDIBAPS Biobank following the guidelines of the Spanish legislation on this matter and the approval of the local ethics committees. The postmortem interval between death and tissue processing was between 2 and 18 hours. One hemisphere was immediately cut into 1-cmthick coronal sections, and selected brain areas were rapidly dissected, frozen on metal plates over dry ice, placed in individual air-tight plastic bags and stored at À80 C until use. The other hemisphere was fixed by immersion in 4% buffered formalin for 3 weeks. The neuropathological study in control and FTLD-TDP cases was carried out on 20 selected 4-lm-thick dewaxed paraffin sections of representative regions of the frontal, temporal, parietal, motor, primary visual, anterior cingulate and entorhinal cortices, hippocampus, amygdala, basal forebrain, caudate, putamen, globus pallidus, thalamus, midbrain, pons, medulla oblongata, cerebellar vermis, hilus, and cerebral white matter. These were stained with hematoxylin and eosin, Klüver-Barrera, or processed for immunohistochemistry for microglia (Iba-1, Wako, Richmond, VA), glial acidic protein ([GFAP] , Dako, Gostrup, Denmark), b-amyloid (Dako, clone 6F/3D), phospho-tau (Thermo Scientific, Rockford, IL, clone AT8), a-synuclein (Novocastra, Newcastle, UK, clone KM51), TDP-43 (Abnova, Taipei, Taiwan, clone 2E2-D3), ubiquitin (Dako, Polyclonal Rabbit), and p62 (BD Biosciences, San Jose, Purified Mouse Anti-p62 LCK ligand) using EnVisionþ System peroxidase (Dako), and diaminobenzidine and H 2 O 2 . FTLD-TDP was diagnosed following wellestablished criteria: frontotemporal atrophy, loss of neurons and variable spongiosis in the upper cortical layers, astrocytic gliosis, and presence of TDP-43-immunoreactive inclusions in neurons and dendrites (NCIs, NIIs, and DNs) (1, 11) . The whole series included 16 sporadic cases of FTLD-TDP (71.6 6 9.6 years; 11 men and 3 women), and 14 control cases (66.5 6 8.8 years; 8 men and 6 women). The postmortem delay varied from 2 hours and 15 minutes to 18 hours ($5.4 6 4.0) in the control group, and between 3 hours and 40 minutes and 16 hours ($7.5 6 3.9) in the sFTLD-TDP group. Patients with associated pathologies of the nervous system, excepting early stages of neurofibrillary tangle pathology and mild small blood vessel disease, were not included. Agematched control cases had not suffered from neurologic and psychiatric disorders and did not show alterations other than those permitted in diseased cases. Regarding TDP types: 11 cases were categorized as type A, 1 as type B, and 4 as type C. A summary of cases is shown in Table 1 .
Biochemical studies were carried out in fresh-frozen frontal cortex area 8. Special care was taken to assess premortem and postmortem factors that might interfere with RNA processing and protein integrity (20) . For this reason, all the samples were used in the study of RNA expression because RNA integrity values were suitable for RNA study, whereas 10 samples per group were used for gel electrophoresis and Western blotting of samples showing a preserved band pattern after Coomassie Blue staining. The same 10 cases per group were used in the study of mitochondrial enzymatic activities. Cases excluded were neoplastic diseases affecting the nervous system, metabolic syndrome, hypoxia, and prolonged agonic state (such as those occurring in intensive care units), as well as cases with infectious, inflammatory, and autoimmune diseases, either systemic or limited to the nervous system. Assessed samples did not bear C9ORF72 mutations (21) . No other FTLD-TDP-related genes were systematically analyzed.
Plus Reagent Kit and microarray 7000 G platform from Affymetrix (Santa Clara, CA). Preprocessing of raw data and statistical analyses were performed using bioconductor packages in R programming environment for genes (22) . Complementary DNA (cDNA) was obtained using High-Capacity cDNA Reverse Transcription kit (Applied Biosystems, Foster City, CA) following the protocol of the supplier. Parallel reactions for each RNA sample were run in the absence of MultiScribe Reverse Transcriptase to assess lack of contamination of genomic DNA. Gene selection was based upon their values using a test for differential expression between 2 classes (Student t-test). Selected genes differentially expressed showed an absolute logarithm of fold change >0.5 combined with a p value 0.01. Table 2 shows identification numbers and names of selected TaqMan probes. Most of the tested probes corresponded to deregulated genes as revealed by microarrays; the remainder was selected to assess other key genes of the altered pathways that were not identified as deregulated in the arrays. TaqMan RT-qPCR assays were performed in duplicate for each gene on cDNA samples in 384-well optical plates using 
Gene
TaqMan assay RNA Purification, Retrotranscription Reaction, and RT-qPCR for Detection of 3 R and 4 R Tau Isoforms Tau mRNA isoforms were assessed by using SYBR green quantitative RT-qPCR; 1000 ng of total RNA was used as a template. cDNA samples obtained from the retrotranscription reaction were diluted 1:20 and duplicate SYBR green PCR assays for each gene were performed. For each reaction, 2.5 mL of cDNA was mixed with 1.25 mL of forward primer 10 lM, 1.25 mL reverse primer 10 lM, and 5 mL of PowerUp SYBR Green Master Mix (Applied Biosystems). The reactions were performed following the parameters: 50 C for 2 minutes, 95 C for 10 minutes, and 40 cycles at 95 C for 15 seconds and at 60 C for 1 minute. SYBR green PCR data were captured using the Sequence Detection Software (SDS version 2.2). 3Rtau forward primer sequence: GTCCGTACTCCACC-CAAGTC; 3Rtau reverse: GTTTGTAGACTATTTG-CACCTTC; 4Rtau forward: GGCGGGAAGATGCAGATAA TTAAT; 4Rtau reverse: GTAGACTATTTGCACACTGCC. Parallel assays for each sample were carried out using primers for b-glucuronidase (GUS-b), forward: GTCTGCGGCA TTTTGTCGG; reverse: CACACGATGGCATAGGAATGG as endogenous controls. Mean fold-change values of each experimental group were analyzed by 1-way ANOVA test with post hoc Tukey by using GraphPad Prism version 5.01 (La Jolla, CA) and Statgraphics Statistical Analysis and Data Visualization Software version.1 (Warrenton, VA). 
Gel Electrophoresis and Western Blotting
Frozen samples of the frontal cortex area 8 were homogenized in RIPA lysis buffer (50 mM Tris/HCl buffer, pH 7.4 containing 2 mM EDTA, 0.2% Nonidet P-40, 1 mM PMSF, protease, and phosphatase inhibitor cocktails; Roche Molecular Systems, Pleasanton, CA). Homogenates were centrifuged at 14 000g for 20 minutes. Protein concentration was determined with the BCA method (ThermoFisher Scientific). Equal amounts of protein (12 lg) for each sample were loaded and separated by electrophoresis on 10% sodium dodecyl-sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gels and transferred onto nitrocellulose membranes (Amersham, Freiburg, Germany). Nonspecific binding was blocked by incubation with 3% albumin in PBS containing 0.2% Tween for 1 hour at room temperature. After washing, membranes were incubated overnight at 4 C with 1 of primary antibodies (Table 3) . Protein loading was normalized using an antibody against GAPDH (37 kDa, 1:2500, Abcam, Cambridge, UK). Membranes were then incubated for 1 hour in the appropriate HRP-conjugated secondary antibodies (1:2000, Dako, Santa Clara, CA). Immunocomplexes were revealed with chemiluminescence reagent (ECL, Amersham). Densitometric quantification was carried out with ImageLab v4.5.2 software (Bio-Rad, Hercules, CA).
Isolation of Mitochondrial-Enriched Fractions From Human Brain Tissue
Mitochondria were extracted from frozen frontal cortex (100 mg) under ice-cold conditions. Tissues were minced in ice-cold isolation buffer (IB) containing 0.25 M sucrose, 10 mmol/L Tris, and 0.5 mmol/L EDTA, pH 7.4, and then homogenized and centrifuged at 1000g for 10 minutes. Samples were homogenized with a micropestle using 10 vol buffer per mg of tissue and centrifuged at 1000g for 10 minutes at 4 C. The supernatant (S1) was conserved. The pellet was washed with 2 vol IB and centrifuged under the same conditions. The last supernatant (S2) was combined with S1, mixed, and centrifuged at 10 000g for 10 minutes at 4 C, resulting in the mitochondria-enriched pellet. The supernatant (S3) was discarded and the pellet was washed with 2 volumes IB and centrifuged at 10 000g for 10 minutes at 4 C, thereby obtaining the washed mitochondria-enriched pellet. The supernatant (S4) was discarded and the final pellet was resuspended in 1 vol IB and stored at À80 C. Protein concentration was measured using a SmartspectTMplus spectrophotometer (Bio-Rad) and the Bradford method (Merck, Darmstadt, Germany). The mitochondrial enriched fraction was used for mitochondrial enzymatic activities and for Western blotting. Protein loading (12 lg) was normalized with anti-VDAC (1:500, Abcam). The activities of mitochondrial complexes I, II, IV, and V were analyzed using commercial kits following the instructions of the suppliers (Mitochondrial complex V: Novagen, Merck Biosciences; and Mitochondrial complex I, II, and IV: Abcam). Activity of citrate synthase was evaluated as a quantitative enzyme marker for the presence of intact mitochondria using commercial kits (Abcam). About 25 lg of mitochondria extract was loaded into each well. The enzymatic activities for each mitochondrial complex were expressed as a rate of milli-optical densities per minute normalized with the citrate synthase activity.
Statistical Analysis
The normality of distribution of fold-change values was analyzed with the Kolmogorov-Smirnov test. The nonparametric Mann-Whitney test was performed to compare each group when values did not follow a normal distribution, while the unpaired t-test was used for normal variables. Statistical analysis and graphic design were performed with GraphPad Prism version 5.01 (La Jolla, CA). Results were analyzed with the Student t-test. Outliers were detected using the GraphPad software QuickCalcs (p < 0.05). All data were expressed as mean 6 SEM and significance levels were set at *p < 0.05, **p < 0.01, and ***p < 0.001. Pearson's correlation coefficient was used to assess a possible linear association between 2 continuous quantitative variables.
RESULTS
Main Neuropathological Findings
All sFTLD-TDP cases presented variable neuron loss and microvacuolation in the upper cortical layers, mild astrocytic gliosis in all layers of the cortex and the presence of TDP-43-immunoreactive dystrophic neurites mainly in the upper layers accompanied or not by neuronal cytoplasmic inclusions. Neuronal intranuclear inclusions were extremely rare. About 11 cases were categorized as type A, 1 as type B, and 4 as type C (Table 1 ; Fig. 1 ). Type A was characterized by numerous NCIs and DNs in the upper cortical layers; type B by numerous NCIs in the upper and inner cortical layers; and type C by predominant DNs in the upper cortical layers. p62-immunoreactive inclusions were absent in any brain region.
Microarray Analysis
All samples had enough quality for subsequent analysis after quality control analysis. The cofactors age and gender were not relevant for the analysis. After filtering, 4851 genes were included in the analysis. The analysis to select differentially expressed genes was based on adjusting a linear model with empirical Bayes moderation of the variance. The 538 top variable genes (with nominal p values <0.01 and an absolute logarithm of the fold change !0.5) were represented in a heat map to illustrate common and differing gene expression patterns between control and sFTLD-TDP cases in FC ( Fig. 2A) . We identified 425 genes differentially expressed in sFTLD-TDP compared with controls (5 up and 420 down) (Fig. 2B) . Gene Ontology (GO) database was used to highlight biological categories of differentially regulated genes. Downregulated genes in sFTLD-TDP were involved in neurotransmission and synapsis, neuron architecture, cytoskeleton of axons and dendrites, vesicle trafficking, purine metabolism, mitochondria, and energy metabolism (Table 4) . Raw data are found in https://www.ebi.ac.uk/arrayexpress/; reference number fgsubs #218580.
Gene Expression Validation
RT-qPCR was carried out to assess the expression of 111 selected genes; 81 of them were abnormally regulated in sFTLD-TDP.
TARDBP and C9ORF72, and GFAP TARDBP and C9ORF72 were significantly decreased in sFTLD-TDP compared with controls (p ¼ 0.05 and p ¼ 0.01, respectively) ( Fig. 2A) . GFAP expression was increased (p ¼ 0.003) in sFTLD-TDP (Fig. 3A) .
Cytoskeleton and Neuron Architecture
The expression of 17 genes was analyzed by RT-qPCR; 12 of them showed decreased expression in sFTLD-TDP when compared with controls.
PAK5 (p ¼ 0.005), and RND1 (p ¼ 0.008) showed a significant decrease in sFTLD-TDP (Fig. 3B, C) .
Synapsis and Neurotransmission
The expression of 36 genes was assessed; 30 of them were downregulated in sFTLD-TDP. The expression of the following genes implicated in presynaptic and postsynaptic attachment was significantly decreased in sFTLD-TDP:
and PSD (p ¼ 0.013). Similarly, 15 genes involved in GABAergic and glutamatergic neurotransmission were downregulated in sFTLD-TDP:
Finally, a set of genes involved in synaptic vesicles were significantly deregulated in sFTLD-TDP: (Fig. 4) .
Expression Levels of Genes Involved in Purine Metabolism
The expression of 18 genes was assessed by RT-qPCR; 9 of them were downregulated. AK5 (p ¼ 0.000), AK7 ABLIM2, ACTN4, ACTR3B, ACTR3C, ADD2, ARHGEF2, ARPC5L, BAG4,  BAIAP2, CACNA2D1, CACNB2, CAP2, CAPZA2, CDK5, CDK5R1, CORO2A,  DNAJB6, EPB41L4B, FGF12, ID1, ITGB1BP1, LIMK1, MEF2C, PACSIN1,  PHACTR1, PIP5K1C, PRKCZ, PTK2B, RND1, SCN1B, SCN2B, SCN3B,  SDAD1, SORBS2, STC1 , SYNPO, TPM2, WASF1 (continued) ADGRB1, ARHGAP32, ARHGAP44, ATP1A3, BAIAP2, CABP1, CADPS2,  CDK5, CDK5R1, CHRM1, CLSTN3, DGKI, DLGAP1, DRP2, FRMPD4,  GABBR2, GABRA2, GABRA3, GABRB3, GABRG2, GABRG3, GAP43, GLRA3,  GRIN2A, GRM5, GSK3A, HOMER1, HPCA, KCNC2, LRRTM1, LRRTM2,  MAPK8IP2, MEF2C, PCDH8 , PRKAR2B, PTK2B, SLC17A7, SYN1, SYNPO 3.14 9.97e-08
(continued) ACTN4, AMIGO1, CAB39, CACNA1G, CACNA1H, CACNA1I, CACNA2D1,  CACNB1, CACNB2, CACNG2, CACNG3, CLIC2, DPP10, DPP6, DRD1,  EHD3, FGF12, HOMER1, KCNA1, KCNA3, KCNA4, KCNB2, KCNC2,  KCND3, KCNIP1, KCNIP3, KCNIP4, KCNJ16, KCNJ6, KCNQ2, KCNQ5,  KCNS2, KCNV1, MAPK8IP2, MEF2C, MMP9, OPRL1, PTK2B, PTPN3,  RASGRF1, SCN1B, SCN2A, SCN2B, SCN3B, SCN8A, THY1 3.91 4.16e-11
Regulation of neurotransmitter levels 23 64 CADPS, CADPS2, CDK5, DAGLA, DGKI, DOC2A, DRD1, GABRA2, GFAP, MEF2C, NRXN3, PDE1B, PIP5K1C, RIMS1, RPH3A, SLC17A7, SNAP25, STXBP1, SV2B, SYN1, SYNJ1, SYT1, UNC13A ACTN4, AMIGO1, CAB39, CACNA1G, CACNA1H, CACNA1I, CACNA2D1,  CACNB1, CACNB2, CACNG2, CACNG3, CLIC2, DPP10, DPP6, DRD1,  EHD3, FGF12, HOMER1, KCNA1, KCNA3, KCNA4, KCNB2, KCNC2,  KCND3, KCNIP1, KCNIP3, KCNIP4, KCNJ16, KCNJ6, KCNQ2, KCNQ5,  KCNS2, KCNV1, MAPK8IP2, MEF2C, MMP9, OAZ2, OPRL1, PTK2B,  PTPN3, RASGRF1, SCN1B, SCN2A, SCN2B, SCN3B, SCN8A, THY1 3.86 3.79e-11
(continued) Regulation of vesicle-mediated transport   27  120  ACTN4, ANXA2, AP2S1, BTBD9, CACNA1G, CACNA1I, CADPS2, CDK5,  DOC2A, INPP5F, LRRTM1, LRRTM2, NRP1, PACSIN1, PPARG, PRKCG,  RAB27B, RIMS1, RINT1, RPH3A, SCFD1, SNAP91, STXBP1, SYN1, SYT1,  TBC1D9, VSNL1   1.86  5.74e-03   Somatodendritic  compartment   54  205  AMIGO1, ARHGAP32, ARHGAP44, ARHGEF2, ATP1A3, ATP2B1, BAIAP2,  CCK, CDK5, CDK5R1, CHL1, CHRM1, CPNE5, DDN, DGKI, DRP2, ELK1,  ENC1, FRMPD4, GABRA2, GLRA3, GLRX2, GNAQ, GNG3, GRK4, GRM2,  HPCA, INPP5F, KCNA1, KCNB2, KCNC2, KCND3, KCNIP1, KCNIP3,  KCNK1, MAPK8IP2, NRP1, NRSN2, PCDH8, PCSK2, PDE1B, PLK2, PNOC Synapse part  63  190  ADGRB1, AMPH, AP1S1, ARHGAP32, ARHGAP44, ATP1A3, ATP2B1, BAIAP2,  CABP1, CADPS, CADPS2, CCK, CDK5, CDK5R1, CHRM1, CLSTN3, DDN,  DGKI, DLGAP1, DOC2A, DRP2, FRMPD4, GABBR2, GABRA2, GABRA3,  GABRB3, GABRG2, GABRG3, GAP43, GLRA3, GRIN2A, GRM2, GRM5,  GSK3A, HOMER1, HPCA, ICA1, KCNA1, KCNC2, LRRTM1, LRRTM2, MAP-K8IP2, MEF2C, NRXN3, OLFM2, PCDH8, PIP5K1C, PRKAR2B, PRKCG,  PTK2B, RIMS1, RPH3A, SLC17A7, SNAP25, STXBP1, SV2B, SYN1, SYNJ1 , SYNPO, SYP, SYT1, UNC13A, VAMP1
3.41 1. 79e-12   Synaptic membrane  35  89  ARHGAP32, ATP2B1, CABP1, CADPS2, CDK5, CHRM1, CLSTN3, DDN, DGKI,  DLGAP1, DRP2, GABBR2, GABRA2, GABRA3, GABRB3, GABRG2,  GABRG3, GLRA3, GRIN2A, GRM2, HOMER1, KCNA1, KCNC2, LRRTM1,  LRRTM2, OLFM2, PCDH8, PRKCG, RIMS1, SNAP25, SYNJ1 , SYNPO, SYP, SYT1, UNC13A (continued)
NME7 (p ¼ 0.007), and POLR3B (p ¼ 0.003) were significantly deregulated in sFTLD-TDP (Fig. 5 ).
Protein Expression Levels of Selected Genes
Expression levels of 14 proteins not related to mitochondria and energy metabolism were assessed. C9ORF72 protein levels were significantly decreased in sFTLD-TDP (p ¼ 0.01). However, TDP-43 levels were increased in sFTLD-TDP (p ¼ 0.02) (Fig. 6 ). Significant reduction of VGAT (p ¼ 0.04) and GAD1 (p ¼ 0.02) levels occurred in sFTLD-TDP. A significant reduction was found in GABRD protein levels (p ¼ 0.02), but no changes were detected in synaptophysin (SYP), NMDAR2A, GABAARB2, calbindin-28K (CALB1), and SNAP25 levels in sFTLD-TDP. GFAP levels showed a nonsignificant increase in sFTLD-TDP cases when compared with controls (Fig. 6 ).
Total TAU, 4R-TAU and 3R-TAU
To further analyze cytoskeletal anomalies, the expression levels of total TAU, 3R-TAU, and 4R-TAU were assessed using forward SYBR primer and reverse primer specific probes. Total Tau, 3R-TAU, and 4R-TAU mRNA expression levels were similar in sFTLD-TDP cases when compared with controls. In this line, 4R/3R ratio was preserved in sFTLD cases. Protein expression was studied with Western blotting. Total TAU protein levels were similar in sFTLD-TDP and controls and the ratio 4R/3R was not modified. Finally, no evidence of increased tau phosphorylation, as revealed with the phospho-tauThr181 antibody was found in sFTLD-TDP (Fig. 7) .
Mitochondrial Alterations
Genes Coding for Mitochondrial Subunits and Energy Metabolism
The expression of 37 genes was assessed by RT-qPCR; 27 of them were deregulated in sFTLD-TDP. Downregulated genes encoded subunits of the electron transport chain (ETC) complexes I: 4. mRNA expression levels of selected deregulated genes identified by microarray analysis in frontal cortex area 8 of sFTLD-TDP and controls assessed by TaqMan RT-qPCR assays are coding for glutamatergic and GABAergic-related genes and corresponding ionotropic and metabotropic receptors, as well as synaptic cleft proteins and neurotransmission vesicles system. Significant levels set at *p < 0.05, **p < 0.01, and ***p < 0.001. (Fig. 8A) .
Mitochondria Protein Levels in Mitochondria-enriched Fractions
Decreased levels of NDUFB10 were found in sFTLD-TDP (p ¼ 0.04), but not of NDUFB8, NDUFS8, NDUFA10. Protein levels of SDHB, a component of ETC complex II, were not modified in sFTLD-TDP. In contrast, UQCRC2, a component of ETC complex III, was significantly increased in sFTLD-TDP (p ¼ 0.03). Levels of ATP5A were significantly decreased (p ¼ 0.04). MT-CO1 levels were significantly decreased in sFTLD-TDP (p ¼ 0.01) but MT-ND1 expression was preserved (Fig. 8B) . In contrast to mRNA expression, TOMM70 protein levels were not significantly altered in pathological cases when compared with controls.
Mitochondrial Enzymatic Activities in Mitochondrial Enriched Fractions
The enzymatic activity of mitochondrial complexes I, IV, and V was significantly reduced in sFTLD-TDP cases when compared with controls (p ¼ 0.04, p ¼ 0.03, and p ¼ 0.05, respectively) (Fig. 8C) .
DISCUSSION
Gene transcription profiles are analyzed in the frontal cortex area 8 in sFTLD cases with typical neuropathology including TDP-43-immunoreactive inclusions mainly in the form of cortical neurites and intracytoplasmic inclusions. Cases in this series had reduced TARDBP mRNA expression and increased levels of TDP-43 protein, and reduced expression of C9Orf72 mRNA and protein. Opposite expression of TDP mRNA and protein may be related to translational modifications. These are further accompanied by posttranslational modifications of TDP-43 (10) . Decreased C9Orf72 mRNA and protein was not expected and further studies are needed to elucidate C9Orf72 loss of function in sFTLD-TDP not linked to C9ORF72 mutations.
The present study using whole-transcriptome microarray hybridization showed downregulation of several genes in FIGURE 5 . mRNA expression levels of selected deregulated genes identified by microarray analysis in frontal cortex area 8 of sFTLD-TDP and controls assessed with TaqMan RT-qPCR assays coding for purines metabolism. Significant levels set at *p < 0.05, **p < 0.01, and ***p < 0.001. the frontal cortex area 8 in sFTLD-TDP clustered in pathways involved in neurotransmission and synapsis, neuronal architecture, cytoskeleton of axons and dendrites, vesicle trafficking, purine metabolism, mitochondria, and energy metabolism. Microarray observations were further validated by RT-qPCR of selected genes from predicted altered pathways after searching on Gene Ontology (GO) database, using 111 probes; the expression of 81 genes was significantly deregulated in this cortical region in sFTLD-TDP when compared with controls. Expression levels of 24 proteins were analyzed by Western blotting; levels of 8 proteins were altered in sFTLD-TDP. Neurotransmission was markedly affected in sFTLD-TDP involving downregulated gene expression of glutamate decarboxylase, several types and subunits of ionotropic and metabotropic glutamate and GABA receptors, neuronal vesicular and soluble glutamate transporters, and various synaptic proteins, together with loss of calbindin expression. This provides robust support to preliminary observations showing decreased numbers, amputation, and proximal swellings of dendritic branches and loss of synaptic spine pyramidal cells, and loss of calbindin-immunoreactive neurons and atrophy of remaining neurons in layers II and III of the frontal cortex in FTLD (24) . Protein expression studies showing decreased levels of synaptic markers are also in line with previous observations demonstrating reduced levels of several synaptic and presynaptic plasma membrane proteins in the frontal cortex, but not in the posterior parietal cortex assessed in parallel, in FTLD (25) . In contrast to the marked decrease in the expression of cytoskeletal and synaptic markers, tau mRNA and protein levels were preserved in the present series, and tau phosphorylation was not increased in sFTLD-TDP. This is in contrast with FIGURE 6 . Gel electrophoresis and Western blotting of proteins involved in toxic aggregates in FTLD, GABAergic, and glutamatergic neurotransmission systems, synaptic vesicles, cytoskeleton, neuroinflammation, and mitochondria. Significant levels set at *p < 0.05, **p < 0.01, and ***p < 0.001.
early reports pointing to decreased tau protein levels in FTLD with ubiquitin inclusions (presumably FTLD-TDP), which suggested that FTLD-U may be a novel "inverse" tauopathy because of the reduced levels of tau (26, 27) . Reduced tau mRNA and protein levels have been reported in FTLD-TDP linked to GRN mutations but not in other FTLD-TDP subtypes including sporadic FTLD-TDP and FTLD-TDP-C9ORF72 (28) .
Mitochondrial alterations compromise mRNA expression of several subunits of the mitochondrial complexes. Moreover, they are accompanied by altered protein expression of several subunits and with reduced activity of complexes I, IV, and V in sFTLD-TDP. Importantly, in addition to mitochondrial subunits encoded by genomic DNA, expression levels of MT-CO1 encoded by mitochondrial DNA are reduced in sFTLD-TDP. Therefore, mitochondrial alterations in sFTLD-TDP have both genomic and mitochondrial components. Other genes involved in energy metabolism are downregulated as well, thus indicating functional energy metabolism failure in sFTLD-TDP. Gene-specific mitochondrial dysfunction has been described in human fibroblasts bearing mutations in TARDBP and C9ORF72 (29) . Mitochondrial dysfunction has also been documented in a transgenic knock-in mouse model for TDP-43 (30) . Therefore, mitochondrial alterations seem to be common to different forms of sFTLD-TDP and fFTLD-TDP.
Purines and pyrimidines are components of a large number of key molecules. The primary purines adenine and guanosine, and pyrimidines cytosine, thymidine, and uracyl, are the core of DNA, RNA, nucleosides, and nucleotides involved in energy transfer (ATP, GTP) and coenzymes (NADH, FADH2) (31, 32) . Alterations in the expression of genes encoding enzymes of purine metabolism may interfere with numerous metabolic processes in sFTLD-TDP.
It can be argued that differences in the percentage of neurons, astrocytes, oligodendroglia, and microglia lie beyond distinct patterns of gene expression, protein levels, and mitochondrial enzymatic activities in sFTLD-TDP. Certainly, neuron loss, spongiosis in the upper cortical layers and variable astrocytic gliosis are typical morphological alterations in sFTLD-TDP (1-3). Present findings complement morphological observations by biochemical data that identify damage of particular components of vital molecular pathways and essential modulators of synaptic transmission.
Previous studies have shown differential gene expression in frontal cortex between 6 cases of FTLD-U A distinct molecular phenotype was identified for GRNþ FTLD-U when compared with GRN-FTLD-U subtypes. Validation by RT-qPCR was assessed for 16 genes; deregulated biological processes associated with GRN-FTLD-U were lipid metabolism, MAPK signaling pathways, and transport (15) . A recent study in the cerebellum and frontal cortex in sALS and ALS linked to C9ORF72 mutations has shown 57 genes in cerebellum and 32 genes in frontal cortex abnormally expressed in both c9ALS and sALS; however, the number of deregulated genes in C9ORF72 sALS cases was double than in sALS thus further suggesting differences between different forms of ALS (19) .
Comparison between present findings and our previous observations in frontal cortex area 8 in sALS (18) , using the same methods, is worth stressing since most of downregulated genes in sFTLD-TDP are upregulated in the frontal cortex area 8 in sALS cases without dementia (18) . This suggests a primary response to synaptic and neurotransmission disturbances of frontal cortex area 8 at preclinical stages of frontal degeneration in sALS. Reduced expression of genes encoding actin, actin-related members, kinesin, and microtubuleassociated protein further supports cytoskeletal damage in sALS and sFTLD-TDP.
Conclusions
Whole transcriptome arrays and bioinformatics processing followed by RT-qPCR expression of 111 genes shows deregulation of 81 genes involved in cytoskeleton and neuron structure, neurotransmitters, receptors, transporters and synaptic proteins, components of mitochondrial function and energy metabolism, enzymes involved in purine metabolism and RNA splicing in sFTLD-TDP. Western blotting of selected proteins further supports alterations of these pathways at translational level. Finally, altered mitochondrial activity of several mitochondrial complexes is demonstrated by enzymatic assays.
